Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference

TEL AVIV, Israel, Nov. 07, 2017

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that its senior management will provide an overview of the scientific rationale and ongoing clinical development program of Aramchol™, a novel, once-daily, oral therapy for the treatment of NASH at the Stifel 2017 Healthcare Conference, being held at the Lotte New York Palace Hotel in New York City.

Galmed Pharmaceuticals Presentation Details:

Date: Wednesday, November 15
Time: 10:15 am Eastern Time
Location: Garrison room, 5^th Floor

About Aramchol™ and Non-alcoholic Steatohepatitis (NASH)

Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol™'s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.